Back to discover

Protein / target

Cyclin-dependent kinase 5

Encoded byCDK5Q00535Homo sapiensSwiss-Prot
Clinical-stage
Therapeutic maturity
7
Clinical candidates
Small-molecule tractable
Druggability
Advanced Clinical
1
Research papers

Protein at a glance

Biological role

Cyclin-dependent protein serine/threonine kinase

Strongest disease association

Alzheimer's Disease

Via encoding gene CDK5 · Literature evidence · score 0.68

Therapeutic position

Clinically advancing target

Small molecules

Research activity

Emerging research

1 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Proline-directed serine/threonine-protein kinase essential for neuronal cell cycle arrest and differentiation and may be involved in apoptotic cell death in neuronal diseases by triggering abortive cell cycle re-entry.

View complete UniProt function annotation

Proline-directed serine/threonine-protein kinase essential for neuronal cell cycle arrest and differentiation and may be involved in apoptotic cell death in neuronal diseases by triggering abortive cell cycle re-entry. Interacts with D1 and D3-type G1 cyclins. Phosphorylates SRC, NOS3, VIM/vimentin, p35/CDK5R1, MEF2A, SIPA1L1, SH3GLB1, PXN, PAK1, MCAM/MUC18, SEPT5, SYN1, DNM1, AMPH, SYNJ1, CDK16, RAC1, RHOA, CDC42, TONEBP/NFAT5, MAPT/TAU, MAP1B, histone H1, p53/TP53, HDAC1, APEX1, PTK2/FAK1, huntingtin/HTT, ATM, MAP2, NEFH and NEFM. Regulates several neuronal development and physiological processes including neuronal survival, migration and differentiation, axonal and neurite growth, synaptogenesis, oligodendrocyte differentiation, synaptic plasticity and neurotransmission, by phosphorylating key proteins. Negatively regulates the CACNA1B/CAV2.2 -mediated Ca(2+) release probability at hippocampal neuronal soma and synaptic terminals (By similarity). Activated by interaction with CDK5R1 (p35) and CDK5R2 (p39), especially in postmitotic neurons, and promotes CDK5R1 (p35) expression in an autostimulation loop. Phosphorylates many downstream substrates such as Rho and Ras family small GTPases (e.g. PAK1, RAC1, RHOA, CDC42) or microtubule-binding proteins (e.g. MAPT/TAU, MAP2, MAP1B), and modulates actin dynamics to regulate neurite growth and/or spine morphogenesis. Also phosphorylates exocytosis associated proteins such as MCAM/MUC18, SEPT5, SYN1, and CDK16/PCTAIRE1 as well as endocytosis associated proteins such as DNM1, AMPH and SYNJ1 at synaptic terminals. In the mature central nervous system (CNS), regulates neurotransmitter movements by phosphorylating substrates associated with neurotransmitter release and synapse plasticity; synaptic vesicle exocytosis, vesicles fusion with the presynaptic membrane, and endocytosis. Promotes cell survival by activating anti-apoptotic proteins BCL2 and STAT3, and negatively regulating of JNK3/MAPK10 activity. Phosphorylation of p53/TP53 in response to genotoxic and oxidative stresses enhances its stabilization by preventing ubiquitin ligase-mediated proteasomal degradation, and induces transactivation of p53/TP53 target genes, thus regulating apoptosis. Phosphorylation of p35/CDK5R1 enhances its stabilization by preventing calpain-mediated proteolysis producing p25/CDK5R1 and avoiding ubiquitin ligase-mediated proteasomal degradation. During aberrant cell-cycle activity and DNA damage, p25/CDK5 activity elicits cell-cycle activity and double-strand DNA breaks that precedes neuronal death by deregulating HDAC1. DNA damage triggered phosphorylation of huntingtin/HTT in nuclei of neurons protects neurons against polyglutamine expansion as well as DNA damage mediated toxicity. Phosphorylation of PXN reduces its interaction with PTK2/FAK1 in matrix-cell focal adhesions (MCFA) during oligodendrocytes (OLs) differentiation. Negative regulator of Wnt/beta-catenin signaling pathway. Activator of the GAIT (IFN-gamma-activated inhibitor of translation) pathway, which suppresses expression of a post-transcriptional regulon of proinflammatory genes in myeloid cells; phosphorylates the linker domain of glutamyl-prolyl tRNA synthetase (EPRS) in a IFN-gamma-dependent manner, the initial event in assembly of the GAIT complex. Phosphorylation of SH3GLB1 is required for autophagy induction in starved neurons. Phosphorylation of TONEBP/NFAT5 in response to osmotic stress mediates its rapid nuclear localization. MEF2 is inactivated by phosphorylation in nucleus in response to neurotoxin, thus leading to neuronal apoptosis. APEX1 AP-endodeoxyribonuclease is repressed by phosphorylation, resulting in accumulation of DNA damage and contributing to neuronal death. NOS3 phosphorylation down regulates NOS3-derived nitrite (NO) levels. SRC phosphorylation mediates its ubiquitin-dependent degradation and thus leads to cytoskeletal reorganization. May regulate endothelial cell migration and angiogenesis via the modulation of lamellipodia formation. Involved in dendritic spine morphogenesis by mediating the EFNA1-EPHA4 signaling. The complex p35/CDK5 participates in the regulation of the circadian clock by modulating the function of CLOCK protein: phosphorylates CLOCK at 'Thr-451' and 'Thr-461' and regulates the transcriptional activity of the CLOCK-BMAL1 heterodimer in association with altered stability and subcellular distribution

Subcellular location

CytoplasmNucleusCell membranePerikaryonCell projection, lamellipodiumCell projection, growth conePostsynaptic densitySynapse
Domains and Gene Ontology detail (66)

Domains & features

Protein kinase

Gene Ontology

  • Caxon
  • Ccyclin-dependent protein kinase holoenzyme complex
  • Ccytoplasm
  • Ccytosol
  • Cdendrite
  • Cfilopodium
  • Cgrowth cone
  • Clamellipodium
  • Cmembrane
  • Cneuromuscular junction
  • Cneuron projection
  • Cneuronal cell body

292 aa · 33 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell-cycle regulationUniProt · GOExcitatory neurotransmissionGOCell proliferation & survivalUniProtCell migrationUniProtKinase signallingUniProt · GOProteolysisUniProt · GO
View supporting evidence

Cell-cycle regulation

  • ·Proline-directed serine/threonine-protein kinase essential for neuronal cell cycle arres…
  • ·regulation of cell cycle phase transition

Excitatory neurotransmission

  • ·regulation of synaptic transmission, glutamatergic

Cell proliferation & survival

  • ·Proline-directed serine/threonine-protein kinase essential for neuronal cell cycle arres…

Cell migration

  • ·Proline-directed serine/threonine-protein kinase essential for neuronal cell cycle arres…

Kinase signalling

  • ·Proline-directed serine/threonine-protein kinase essential for neuronal cell cycle arres…
  • ·cyclin-dependent protein kinase holoenzyme complex
  • ·protein kinase 5 complex
  • ·cyclin-dependent protein serine/threonine kinase activity

Proteolysis

  • ·Proline-directed serine/threonine-protein kinase essential for neuronal cell cycle arres…
  • ·negative regulation of proteolysis

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene CDK5

Gene-level evidence surfaced through the gene CDK5that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Alzheimer's Disease
0.45Preliminary

Pathway evidence dominant · Open Targets 0.68 · no direct causal or clinical evidence

Leukemia, Lymphocytic, Chronic, B-Cell
0.37Limited support

Clinical evidence dominant · Open Targets 0.30

Neurodegenerative Diseases
0.34Preliminary

Pathway evidence dominant · Open Targets 0.48 · no direct causal or clinical evidence

Parkinson's Disease
0.33Preliminary

Pathway evidence dominant · Open Targets 0.38 · no direct causal or clinical evidence

Autoimmune disorder of central nervous system
0.24Preliminary

Pathway evidence dominant · Open Targets 0.37 · no direct causal or clinical evidence

View evidence synthesis (5)
Alzheimer's DiseasePreliminary
0.45
agreement 0.310.60
Pathway69%Literature28%RNA expression4%

Open Targets aggregate 0.68 · 3 independent evidence families · no direct causal or clinical evidence

Leukemia, Lymphocytic, Chronic, B-CellLimited support
0.37
agreement 0.210.52
Clinical98%Literature2%

Open Targets aggregate 0.30 · 2 independent evidence families

Neurodegenerative DiseasesPreliminary
0.34
agreement 0.160.51
Pathway88%Literature12%

Open Targets aggregate 0.48 · 2 independent evidence families · no direct causal or clinical evidence

Parkinson's DiseasePreliminary
0.33
agreement 0.150.51
Pathway65%Literature35%

Open Targets aggregate 0.38 · 2 independent evidence families · no direct causal or clinical evidence

Autoimmune disorder of central nervous systemPreliminary
0.24
agreement 0.010.47
Pathway100%

Open Targets aggregate 0.37 · 1 independent evidence family · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Alzheimer's Disease0.68
Neurodegenerative Diseases0.48
Parkinson's Disease0.38
Autoimmune disorder of central nervous system0.37
Multiple Sclerosis0.35
Lysosomal Storage Diseases0.35
Leukemia, Lymphocytic, Chronic, B-Cell0.30
Breast Neoplasms0.13

Drug development

7 compounds recorded · 7 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines.

View all recorded compounds (7)
RONICICLIBPhase 2
AT-7519Phase 2
SELICICLIBPhase 2
DINACICLIBPhase 3
AZD-5438Phase 1
RGB-286638Phase 1
PHA-793887Phase 1

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Advanced Clinical and Structure with Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (literature and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (13)
SM · Advanced ClinicalSM · Structure with LigandSM · High-Quality LigandSM · Med-Quality PocketSM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confAB · UniProt loc med confAB · Human Protein Atlas locPR · LiteraturePR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Larose A · Cellular and molecular life sciences : CMLS · 2024

Recent

Europe PMC papers linked directly to this protein.

Related family literature

5

Papers about “Cyclin-Dependent Kinases” — a broader family this protein belongs to. Shown as context; not counted as papers specifically about this protein.

Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.

Nguyen CB · Clinical cancer research : an official journal of the American Association for Cancer Research · 2024

via Cyclin-Dependent Kinases

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

Hussain M · The New England journal of medicine · 2020

via Cyclin-Dependent Kinases

Malignant glioma: genetics and biology of a grave matter.

Maher EA · Genes & development · 2001

via Cyclin-Dependent Kinases

Europe PMC literature, reached through curated HGNC family membership. Membership is a taxonomic relationship — it does not imply this protein participates in every mechanism these papers discuss.